Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -598.82
- Piotroski Score 2.00
- Grade Buy
- Symbol (IMRX)
- Company Immuneering Corporation
- Price $1.98
- Changes Percentage (6.18%)
- Change $0.12
- Day Low $1.86
- Day High $1.98
- Year High $8.89
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $13.00
- High Stock Price Target $41.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.86
- Trailing P/E Ratio -0.74
- Forward P/E Ratio -0.74
- P/E Growth -0.74
- Net Income $-53,471,622
